| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID6196: Lenacapavir for treating multidrug resistant HIV-1 |
|
Medicine details |
|
| Medicine name | lenacapavir (Sunlenca®) |
| Formulation | Oral formulation of Sunlenca (lead in) is followed by subcutaneous Sunlenca injection |
| Reference number | 4845 |
| Indication | In combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug‑resistant HIV‑1 infection for whom it is otherwise not possible to construct a suppressive anti‑viral regimen, for oral loading prior to administration of long-acting lenacapavir injection |
| Company | Gilead Sciences Ltd |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/05/23 |
| NICE guidance | |